Orlando Tamariz-Cruz O, Salguero-Ruiz C

Language: Spanish
References: 29
Page: 56-66
PDF size: 129.79 Kb.

ABSTRACT

Pulmonary thromboembolism (PTE) in the perioperative field is –besides being devastating– a real therapeutic challenge, since the circumstances surrounding this pathology are very serious. In several occasions, we face the impossibility of performing a thrombolisis, due to an immediate postoperative state, or we have to take the patient to urgency surgery since he/she has developed pulmonary thromboemboli. This last fact complicates and reduces the therapeutic spectrum and it is associated to high perioperative mortality. This paper reviews the both the diagnostic approach of patients suffering from thromboembolism and the management strategies based upon evidence, with regard to effectiveness. It is described the most commonly employed medicines, such as heparins of low molecular weight, thrombolitics (streptokinase, alteplase), the hemodynamic management of the patients with (secondary) cardiogenic shock and the interventions, both surgical and percutaneous (embolectomy or catheter embolectomy). Finally, it is proposed a management and diagnosis algorithm for the surgical patient.

REFERENCES

1. Dehring D, Arens JF. Pulmonary thromboembolism: Disease recognition and patient management. Anesthesiology 1990;73:146-164.

2. Wood KE. Massive pulmonary embolism. Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877-905.

3. Golhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Registry (ICOPER). Lancet 1999;353:1386-1389.

4. Kasper W, Konstantinides S, Gebel A. Management strategies and determinants of outcome in acute major pulmonary embolism results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171.

5. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. JAMA 1986;255:2039-2042.

6. De Maria EJ, Carmody BJ. Perioperative management of special populations: Obesity. Surg Clin North Am 2005;85:1283-1289.

7. Buck JR, Connors RH, Coon WW, et al. Pulmonary embolism in children. J Pediatr Surg 1981;16:385-391.

8. Geerts WH, Pinco GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.

9. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without cardiopulmonary disease. Am J Cardiol 1971;28:288-294.

10. Weidemann HP, Matthay RA. Acute right heart failure. Crit Care Clin 1985;1:631-661.

11. Goldhaber SZ. Pulmonary embolism. NEJM 1998;339:93-104.

12. Baker WF. Thrombolytic therapy. Current clinical practice. Hematol Oncol Clin N Am 2005;19:147-181.

13. Modig J, Borg T, Karlstrom G, Maripuu E, Sahlstedt B. Thromboembolism after total hip replacement: Role of epidural and general anesthesia. Anesth Analg 1983;62:174-180.

14. Hendolin H, Mattila MA, Poikolainen E. The effect of lumbar epidural anesthesia on the development of deep vein thrombosis of the legs after open prostatectomy. Acta Chir Scand 1991;147:425-429.

15. Mellbring G, Dahlgren S, Reiz S, Sunnegardh O. Thromboembolic complications after major abdominal surgery: Effect of thoracic epidural analgesia. Acta Chir Scand 1983;149:263-268.

16. Jardin F, Genevray B, Brun-Ney D, et al. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985;13:1009-1012.

17. Bayram M, De Luca L, Massie B, Gheorghiade M. Reassessment of dobutamine, dopamine and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G.

18. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta adrenergic signaling in heart failure. Circ Res 2003;93:896-906.

19. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME –CHF study. J Am Coll Cardiol 2003;41:997-1003.

20. Gold J, Cullinane S, Chen J, et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000;85:506-508, A511.

21. Dünser MW, Mayr A, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock. Circulation 2003;107:2313-2319.

22. Bhorade S, Christenson J, O’Connor M, et al. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999;159:571-579.

23. Büller HR, Ahnelli G, Hull RD, Hyers TM, et al. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S.

24. Stewart JR, Greenfield LJ. Transvenous vena caval filtration and pulmonary embolectomy. Surg Clin North Am 1982;62:411-430.

25. Koning R, Cribier A, Gerber L. A new treatment for severe pulmonary embolism: percutaneous rheolytic embolism. Chest 1991;100:655-658.

26. Schmitz-Rode, Janssens E, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. Chest 1998;114:1427-1436.

27. Mateos M, Tamariz-Cruz O, Palacios-Macedo A. Manejo de paciente sometido a tromboendarterectomía pulmonar: Papel del óxido nítrico. Reporte de un caso. Rev Mex Anest 2003;26:21-23.

28. Becker DW, Philbrick JT, Sleby JB. Inferior vena cava filters: Indications, safety and effectiveness. Arch Int Med 1992;152:1985-1994.

29. Villagómez A de J, Carrillo R, Alcántara E y cols. Guías para el diagnóstico, prevención y tratamiento de la enfermedad tromboembólica venosa. Rev Mex Anest 2006;29:S304-S334.